Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s patents for its COVID-19 vaccine technology. The final written decisions remain sealed. U.S. Patent Nos. 10,933,127 (IPR2023-01359) and 10,702,600 (IPR2023-01358) are both titled “Betacoronavirus Mrna Vaccine.” Moderna competitors Pfizer and BioNTech filed two petitions for inter partes review (IPR) in August 2023 against certain claims of each of the patents, accusing Moderna of attempting “to coopt an entire field of mRNA technology.”
Recent Posts
- Amici Urge SCOTUS to Address Uncertainty Around ‘After-Arising Technology’ Question
- Other Barks and Bites for Friday, October 10: SCOTUS Invites SG’s Views on RiseandShine’s Trademark Issues; MPA Urges OpenAI to Address Sora 2 Infringement; and UPC to Add Third Panel to Court of Appeal
- IP Experts Remind UKIPO: Global Device Markets Thrive Under Arm’s-Length SEP Licensing
- PERA 2025 Debated in Senate IP Subcommittee Hearing, with Business Methods, Diagnostics in Focus
- Patent Policy in the Trump Administration: What’s Next for the USPTO? | IPWatchdog Unleashed